Aurobindo Pharma's Telangana Unit Successfully Completes USFDA Inspection
Aurobindo Pharma's Telangana Unit completes USFDA inspection
Business Standard
Image: Business Standard
Aurobindo Pharma's Unit-VII in Mahaboobnagar district, Telangana, underwent a USFDA inspection from January 28 to February 10, 2026. The facility received a Form 483 with 9 observations but has now been classified as 'Voluntary Action Indicated' (VAI), marking the inspection as closed.
- 01Aurobindo Pharma's Unit-VII passed a USFDA inspection.
- 02The inspection took place over two weeks from January 28 to February 10, 2026.
- 03A total of 9 observations were noted in the Form 483 issued.
- 04The facility received an Establishment Inspection Report (EIR) classifying it as 'Voluntary Action Indicated' (VAI).
- 05The USFDA has officially closed the inspection.
Advertisement
In-Article Ad
Aurobindo Pharma, a major player in the pharmaceutical industry, announced the successful completion of a USFDA inspection at its Unit-VII located in Polepally Village, Mahaboobnagar District, Telangana. The inspection, which occurred from January 28 to February 10, 2026, resulted in the issuance of a Form 483 detailing 9 observations. Despite these observations, the facility has received an Establishment Inspection Report (EIR) classifying it as 'Voluntary Action Indicated' (VAI). This classification indicates that while there are some issues to address, the FDA does not require immediate corrective action. With the inspection now officially closed, Aurobindo Pharma can continue its operations with the aim of addressing the observations noted by the FDA.
Advertisement
In-Article Ad
The successful inspection allows Aurobindo Pharma to maintain its production capabilities, which is crucial for local employment and the supply of pharmaceutical products.
Advertisement
In-Article Ad
Reader Poll
How important is FDA approval for pharmaceutical companies?
Connecting to poll...
More about Aurobindo Pharma
Read the original article
Visit the source for the complete story.